BACKGROUND: Liver transplantation (LT) is a treatment option for select human immunodeficiency virus (HIV)-infected patients with advanced liver disease. The aim of this study was to describe LT evaluation outcomes in HIV-infected patients. METHODS: All HIV-infected patients referred for their first LT evaluation at the Mount Sinai Medical Center were included in this retrospective, descriptive cohort study. Multivariable logistic regression was used to identify factors independently associated with listing. RESULTS: Between February 2000 and April 2012, 366 patients were evaluated for LT, with 66 (18.0%) listed for LT and 300 (82.0%) not listed. Fifty-one patients (13.9%) died before completing evaluation and 85 (23.2%) were too early for listing. Reasons patients were declined for listing were psychosocial (15.8%), HIV-related (10.4%), loss to follow-up (9.6%), surgical/medical (6.0%), liver-related (4.4%), patient choice (3.4%), and financial (1.6%). Listed patients were more likely to have hepatocellular carcinoma (HCC) (43.1% vs. 17.1%; P < 0.0001) and less likely to have hepatitis B (6.2% vs. 15.7%; P = 0.04) or a psychiatric history (19.7% vs. 35.2%; P = 0.02) than those not listed. In multivariable analysis, HCC (odds ratio [OR] 5.79; 95% confidence interval [95% CI]: 2.97-11.28), model for end-stage liver disease (MELD) score at referral (OR 1.06; 95% CI 1.01-1.11), and hepatitis B (OR 0.26; 95% CI 0.08-0.79) were associated with listing. CONCLUSION: MELD score and HCC were positive predictors of listing in HIV-infected patients referred for LT evaluation and, therefore, timely referrals are vital in these patients. As MELD is a predictor for death while undergoing evaluation, rapid evaluation should be performed in HIV-infected patients with a higher MELD score.
BACKGROUND: Liver transplantation (LT) is a treatment option for select humanimmunodeficiency virus (HIV)-infectedpatients with advanced liver disease. The aim of this study was to describe LT evaluation outcomes in HIV-infectedpatients. METHODS: All HIV-infectedpatients referred for their first LT evaluation at the Mount Sinai Medical Center were included in this retrospective, descriptive cohort study. Multivariable logistic regression was used to identify factors independently associated with listing. RESULTS: Between February 2000 and April 2012, 366 patients were evaluated for LT, with 66 (18.0%) listed for LT and 300 (82.0%) not listed. Fifty-one patients (13.9%) died before completing evaluation and 85 (23.2%) were too early for listing. Reasons patients were declined for listing were psychosocial (15.8%), HIV-related (10.4%), loss to follow-up (9.6%), surgical/medical (6.0%), liver-related (4.4%), patient choice (3.4%), and financial (1.6%). Listed patients were more likely to have hepatocellular carcinoma (HCC) (43.1% vs. 17.1%; P < 0.0001) and less likely to have hepatitis B (6.2% vs. 15.7%; P = 0.04) or a psychiatric history (19.7% vs. 35.2%; P = 0.02) than those not listed. In multivariable analysis, HCC (odds ratio [OR] 5.79; 95% confidence interval [95% CI]: 2.97-11.28), model for end-stage liver disease (MELD) score at referral (OR 1.06; 95% CI 1.01-1.11), and hepatitis B (OR 0.26; 95% CI 0.08-0.79) were associated with listing. CONCLUSION: MELD score and HCC were positive predictors of listing in HIV-infectedpatients referred for LT evaluation and, therefore, timely referrals are vital in these patients. As MELD is a predictor for death while undergoing evaluation, rapid evaluation should be performed in HIV-infectedpatients with a higher MELD score.
Authors: Margaret V Ragni; Bijan Eghtesad; Kimberly W Schlesinger; Igor Dvorchik; John J Fung Journal: Liver Transpl Date: 2005-11 Impact factor: 5.799
Authors: Javier Murillas; Antonio Rimola; Montserrat Laguno; Elisa de Lazzari; Javier Rascón; Fernando Agüero; José L Blanco; Eduardo Moitinho; Asunción Moreno; José M Miró Journal: Liver Transpl Date: 2009-09 Impact factor: 5.799
Authors: M E Roland; B Barin; L Carlson; L A Frassetto; N A Terrault; R Hirose; C E Freise; L Z Benet; N L Ascher; J P Roberts; B Murphy; M J Keller; K M Olthoff; E A Blumberg; K L Brayman; S T Bartlett; C E Davis; J M McCune; B M Bredt; D M Stablein; P G Stock Journal: Am J Transplant Date: 2007-12-18 Impact factor: 8.086
Authors: Aruna Subramanian; Mark Sulkowski; Burc Barin; Donald Stablein; Michael Curry; Nicholas Nissen; Lorna Dove; Michelle Roland; Sander Florman; Emily Blumberg; Valentina Stosor; D T Jayaweera; Shirish Huprikar; John Fung; Timothy Pruett; Peter Stock; Margaret Ragni Journal: Gastroenterology Date: 2009-09-30 Impact factor: 22.682
Authors: Nicolás Merchante; Esperanza Merino; José López-Aldeguer; Francisco Jover; Marcial Delgado-Fernández; Maria José Galindo; Enrique Ortega; Antonio Rivero; Carlos Mínguez; Alberto Romero-Palacios; Sergio Padilla; Manuel Márquez-Solero; Concepción Amador; Maria José Ríos-Villegas; Francisco Téllez; Joaquín Portilla; Juan A Pineda Journal: Clin Infect Dis Date: 2012-09-05 Impact factor: 9.079
Authors: Clara Tan-Tam; Pamela Liao; Julio S Montaner; Mark W Hull; Charles H Scudamore; Siegfried R Erb; Eric M Yoshida Journal: Can J Infect Dis Med Microbiol Date: 2014-05 Impact factor: 2.471
Authors: Julia M Grottenthaler; Christoph R Werner; Martina Steurer; Ulrich Spengler; Thomas Berg; Cornelius Engelmann; Heiner Wedemeyer; Thomas von Hahn; Wolfgang Stremmel; Anita Pathil; Ulrich Seybold; Eckart Schott; Usha Blessin; Christoph Sarrazin; Martin-Walter Welker; Ellen Harrer; Stefan Scholten; Clemens Hinterleitner; Ulrich M Lauer; Nisar P Malek; Christoph P Berg Journal: PLoS One Date: 2018-06-06 Impact factor: 3.240